Variable | Total | ||
---|---|---|---|
N | % | ||
Age at inclusion (years) | Median (range) | 59 (20–81) | |
Gender | Male | 38 | 63 |
Female | 22 | 37 | |
ECOG PS | 0 | 28 | 47 |
1 | 32 | 53 | |
T stage | T2 | 3 | 6 |
T3 | 24 | 45 | |
T4a | 16 | 30 | |
T4b | 6 | 11 | |
Tx | 4 | 8 | |
N stage | N0 | 11 | 21 |
N1 | 17 | 33 | |
N2a | 15 | 29 | |
N2b | 4 | 8 | |
Nx | 5 | 10 | |
Metastatic sitesb | Liver | 46 | 77 |
Lung | 45 | 52 | |
Peritoneal cavity | 14 | 23 | |
Others | 10 | 17 | |
Number of metastatic sites | 1 | 10 | 17 |
2 | 27 | 45 | |
3 | 16 | 27 | |
> 3 | 7 | 17 | |
Prior treatments | Surgery | 49 | 82 |
Radiotherapy | 19 | 68 | |
Chemotherapy + TT | 58 | 97 | |
Median N lines (range) | 2 (1–5) | ||
Molecular status | PDL1 ≥ 1% | 11 | 18 |
MSS NA | 19 | 32 | |
pMMR | 33 | 55 | |
MSI-H | 8a | 13 | |
KRAS/NRAS | 25 | 42 | |
HER2 | 3 | 5 | |
MET | 1 | 2 | |
PI3KCA | 1 | 2 | |
BRAF | 6 | 10 | |
Atezolizumab | median N cycles (range) | 4 (1–94) | |
SBRT (Gy) | Median dose (range) | 45 (21–45) | |
Irradiated sites | Lung | 30 | 56 |
Liver | 18 | 33 | |
Others | 8 | 13 |